The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.

This program features world-renowned experts who will review the current standard of care for patients with breast cancer, the latest NCCN Guidelines recommendations, and recent clinical research updates.

Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

Pharmacists should be aware of the treatment recommendations for this rare disease type so they can support patients as well as the health care team in making informed treatment decisions. It is also important to be aware of the potential adverse events that can occur with these therapies since pharmacists frequently provide patient education and monitoring related to this in order to avoid severe complications and maximize treatment outcomes.